Early Alzheimer’s Disease

Memory loss isn’t normal. Could your memory loss be more than aging?

A clinical research study for those with symptoms of early Alzheimer’s disease. If you or a loved one are experiencing problems with memory or challenges performing complex tasks, you may qualify for a clinical research study for those with symptoms of early Alzheimer’s disease.

Welcome to the PROSPECT-ALZ Study, where we’re exploring a potential treatment to delay or slow the progression of Alzheimer’s.

We’re looking for men and women ages 60-85 who have shown a gradual decline in their memory function over the last 6 months or more to help us evaluate an investigational medicine to see if it might potentially delay or slow memory decline.

About Early Symptomatic Alzheimer’s Disease

Early symptomatic Alzheimer’s disease causes a small but noticeable and measurable decline in cognitive skills. It involves problems with memory and thinking ability, behavior, and mood.

If you have early symptomatic Alzheimer’s disease, you may be noticing changes in your memory. You may feel like your mental functions are “slipping,” but the changes have not become severe enough to significantly interrupt your daily life.

  • Alzheimer’s disease, a type of dementia, may begin 20 years or more before symptoms arise.
  • Someone with early symptomatic Alzheimer’s disease is at an increased risk of developing Alzheimer’s dementia or another dementia.
  • Approximately 15% to 20 % of people aged 65 or older have mild cognitive impairment (MCI), an indicator of early symptomatic Alzheimer’s disease.
  • Among those with MCI, about 1/3 (32%) develop Alzheimer’s dementia within 5 years.
  • The risk factors most strongly linked to Alzheimer’s disease are advancing age, family history of Alzheimer’s or another dementia, and conditions that raise risk for cardiovascular disease.

THE CAUSES AND TREATMENT OF ALZHEIMER’S DISEASE ARE NOT YET FULLY UNDERSTOOD. CLINICAL RESEARCH STUDIES LIKE PROSPECT-ALZ ARE COMMITTED TO FINDING THE ANSWERS.

The PROSPECT-ALZ Clinical Research Study is researching the safety and effectiveness of an investigational medicine that targets the tau protein, a substance in the brain that supports brain neuron structure and helps nutrients travel to different parts of a cell.

For people with Alzheimer’s disease, tau proteins in the brain break down inside neurons and stick to each other, forming tangles that cause neurons to die and block communication from one part of the brain to another. This study will research whether the investigational medicine can slow or prevent these tangles from forming. Scientists think that this may help to delay or slow memory loss in people with early stages of Alzheimer’s disease.

The study involves people who have memory loss that has gotten worse over the last 6 months or more. If you are experiencing memory loss or struggling to perform complex tasks, you may prequalify.

If you qualify, participation can range from 1 year and 6 months to 2 years and 8 months, with up to 31 appointments with the study center.

Who can participate in the PROSPECT-ALZ Clinical Research Study?

The PROSPECT-ALZ Study is looking for participants to research an investigational medicine for those who have experienced memory loss due to early stages of Alzheimer’s disease. In order to meet study entry requirements, the participant must:

  • Be 60 to 85 years old
  • Have memory loss that has gotten worse over time
  • Have a reliable study partner* who knows you and is willing to go to appointments with you or be available by phone at certain times throughout the study

*The study partner must be able to speak about the participant’s daily routines and any changes with the research staff throughout the study.

There are additional criteria that are reviewed by the study team at the study center at the first appointment.

The study coordinator can answer any more questions you may have about the PROSPECT-ALZ Study. For more information about memory loss, we encourage you to speak with your doctor.

If prequalified, what can I expect on my first visit to the study center?

This initial appointment is an opportunity for you to:

Learn more about the PROSPECT-ALZ Clinical Research Study. You’ll be speaking with a study coordinator at the study center to learn more regarding your participation in this study.

Ask any important questions you may have. These can be any questions you may have about this study or clinical research in general.

Determine if the PROSPECT-ALZ Clinical Research Study may be right for you. The study coordinator will ask you about your health history to determine if you are eligible for the study. If you are eligible, you will be given the opportunity to decide if participation is right for you. If you agree to take part, you will be asked to review and sign a consent form for study participation. Once you have signed the study consent form, the research staff will perform a series of tests to determine if you are right for the study, and if the study is right for you.

How long is this study?

If you qualify, participation can range from 1 year and 6 months to 2 years and 8 months, with up to 31 appointments with the study center. The study coordinator can answer any questions you have about the PROSPECT-ALZ Study.

Will I have to discontinue any current medicine?

Do not discontinue any medicine unless you are advised to do so by the study center staff or your primary care physician.

Does participating in this study cost me anything?

There is no cost to you or your insurance provider for participating in this study. If you qualify for this study, study-related care may be provided at no cost to you.

For U.S. participants: Do I need health insurance to participate?

No, health insurance is not required in order to participate.

This website is for informational purposes only. Please dial 911 for emergency.

Lewy Body Dementia Study
This is default text for notification bar